Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 2/20 | 0.49 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.49 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7819092 | 0.77 | SLC1A3 (0.43) | SLC1A3SLC1A2SLC1A1KMT2ACYP1A2 | |
| SCHEMBL7821068 | 0.77 | SLC1A1 (0.43) | SLC1A3SLC1A2SLC1A1KMT2ACYP1A2 | |
| SCHEMBL4777959 | 0.75 | ALDH1A1 (0.47) | SLC1A3SLC1A2SLC1A1KMT2ACYP1A2 | |
| SCHEMBL431116 | 0.74 | SLC1A1 (0.49) | SLC1A3SLC1A2SLC1A1KMT2ACYP1A2 | |
| SCHEMBL4829905 | 0.74 | SLC1A3 (0.40) | SLC1A3SLC1A2SLC1A1KMT2ACYP1A2 | |
| SCHEMBL4901360 | 0.73 | SLC1A3 (0.38) | SLC1A3SLC1A2SLC1A1KMT2ACYP1A2 | |
| SCHEMBL18497884 | 0.73 | SLC1A1 (0.46) | SLC1A3SLC1A2SLC1A1KMT2ACYP1A2 | |
| SCHEMBL418322 | 0.72 | SLC1A3 (0.76) | SLC1A3SLC1A2SLC1A1KMT2ACYP1A2 | |
| SCHEMBL8553178 | 0.72 | SLC1A1 (0.59) | SLC1A3SLC1A2SLC1A1KMT2ACYP1A2 | |
| SCHEMBL1231110 | 0.72 | SLC1A1 (0.59) | SLC1A3SLC1A2SLC1A1KMT2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117897177-A | Molecular degradation agent for extracellular proteins | 耶鲁大学 | 2024-04-16 | — | — | CN | disclosed |
| CN-111542511-A | Double-headed inhibitors of proteolytic enzymes | 宇部兴产株式会社 | 2020-08-14 | — | — | CN | disclosed |
| EP-1724278-B1 | NITROGENOUS FUSED-RING DERIVATIVES, MEDICINAL COMPOSITIONS CONTAINING THE DERIVATIVES, AND USE THEREOF AS DRUGS | KISSEI PHARMACEUTICAL (JP) | 2014-05-07 | — | — | EP | disclosed |
| CN-102203068-B | Cyclohexane derivative and pharmaceutical use thereof | TORAY INDUSTRIES | 2014-03-19 | — | — | CN | disclosed |
| EP-1548024-B1 | PYRAZOLE DERIVATIVES, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF, AND INTERMEDIATE FOR PRODUCTION THEREOF | KISSEI PHARMACEUTICAL (JP) | 2012-06-06 | — | — | EP | disclosed |
| CN-102203068-A | Cyclohexane derivative and pharmaceutical use thereof | TORAY INDUSTRIES | 2011-09-28 | — | — | CN | disclosed |
| US-7998975-B2 | Sodium dependent glucose transporter inhibition; hyperglycemia associated diseases; 3-glucopyranosyloxy- 1H-indazole and 1H-pyrazolo[3,4-b]pyridine derivatives | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2011-08-16 | — | — | US | disclosed |
| US-20080188426-A1 | NITROGENOUS FUSED-RING DERIVATIVES, MEDICINAL COMPOSITIONS CONTAINING THE DERIVATIVES, AND USE THEREOF AS DRUGS | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2008-08-07 | — | — | US | disclosed |
| US-7375113-B2 | Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2008-05-20 | — | — | US | disclosed |
| US-20080045537-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2008-02-21 | — | — | US | disclosed |
| CN-101039672-A | Chemical compounds | SMITHKLINE BEECHAM CORP (US) | 2007-09-19 | — | — | CN | disclosed |
| US-20070191289-A1 | Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1789045-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-30 | — | — | EP | disclosed |
| EP-1724278-A1 | NITROGENOUS FUSED-RING DERIVATIVES, MEDICINAL COMPOSITIONS CONTAINING THE DERIVATIVES, AND USE THEREOF AS DRUGS | Kissei Pharmaceutical Co., Ltd. (JP) | 2006-11-22 | — | — | EP | disclosed |
| WO-2006023400-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-03-02 | — | — | WO | disclosed |
| CN-1230884-A | Thiol sulfone metalloprotease inhibitors | MONSANTO CO (US) | 1999-10-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191289-A1 | Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs | SLC5A1, SLC5A2, GPR119 | SLC1A3 271/4885SLC1A2 364/4885SLC1A1 257/4885 |
| US-20080045537-A1 | Chemical Compounds | CCR5, CXCR4, CXCR3 | SLC1A3 2844/4885SLC1A2 3389/4885SLC1A1 2327/4885 |
| US-20080188426-A1 | NITROGENOUS FUSED-RING DERIVATIVES, MEDICINAL COMPOSITIONS CONTAINING THE DERIVATIVES, AND USE THEREOF AS DRUGS | SLC5A1, SLC5A2, SLC2A1 | SLC1A3 321/4885SLC1A2 419/4885SLC1A1 274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.